Why the study?
Does tocainide reduce premature ventricular complexes as effectively as lidocaine in patients with suspected acute myocardial infarction?
Does tocainide reduce premature ventricular complexes as effectively as lidocaine in patients with suspected acute myocardial infarction?
Tocainide is as effective as lidocaine in reducing high-grade PVCs in patients with suspected AMI, with potentially fewer infusion-limiting side effects.
Answers are grounded in this paper and cite their sources.
Supports similar PVC suppression by tocainide versus lidocaine in suspected AMI; leaves open effects on tolerability or outcomes.
The antiarrhythmic effects of tocainide, administered as a bolus injection of 750 mg followed by oral therapy, and conventional lidocaine therapy were evaluated in 40 patients admitted for suspected acute myocardial infarction (AMI) and showing high-grade premature ventricular complexes (PVCs). The mean hourly PVC rate before therapy was 928 and its reduction was equally significant in the tocainide group, 73%, and in the lidocaine group, 68%. The number of 5-minute periods with multiform, paired and R/T PVCs or ventricular tachycardia was also significantly reduced, by 78% in the tocainide group and by 71% in the lidocaine group. Ten patients in the tocainide group reported moderate side-effects, compared to 13 in the lidocaine group, where the infusion had to be discontinued in 5 patients and the rate had to be reduced in 4. Tocainide, an amine analogue of lidocaine, is considered just as effective as lidocaine in patients with high-grade PVCs and suspected AMI.
No takes yet. Share an insight, caveat, or question.
Rehnqvist et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: